BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33930844)

  • 1. Discovery of a potent and selective Axl inhibitor in preclinical model.
    Inoue S; Yamane Y; Tsukamoto S; Azuma H; Nagao S; Murai N; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
    Bioorg Med Chem; 2021 Jun; 39():116137. PubMed ID: 33930844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
    Inoue S; Yamane Y; Tsukamoto S; Murai N; Azuma H; Nagao S; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
    Bioorg Med Chem Lett; 2021 Sep; 48():128247. PubMed ID: 34271070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
    Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
    Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.
    Ng PS; Foo K; Sim S; Wang G; Huang C; Tan LH; Poulsen A; Liu B; Tee DHY; Ahmad NHB; Wang S; Ke Z; Lee MA; Kwek ZP; Joy J; Anantharajan J; Baburajendran N; Pendharkar V; Manoharan V; Vuddagiri S; Sangthongpitag K; Hill J; Keller TH; Hung AW
    Bioorg Med Chem; 2021 Nov; 49():116437. PubMed ID: 34600239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.
    Keung W; Boloor A; Brown J; Kiryanov A; Gangloff A; Lawson JD; Skene R; Hoffman I; Atienza J; Kahana J; De Jong R; Farrell P; Balakrishna D; Halkowycz P
    Bioorg Med Chem Lett; 2017 Feb; 27(4):1099-1104. PubMed ID: 28082036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.
    Schoumacher M; Burbridge M
    Curr Oncol Rep; 2017 Mar; 19(3):19. PubMed ID: 28251492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research Progress of Axl Inhibitors.
    Sun ZG; Liu JH; Zhang JM; Qian Y
    Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase.
    Gajiwala KS; Grodsky N; Bolaños B; Feng J; Ferre R; Timofeevski S; Xu M; Murray BW; Johnson TW; Stewart A
    J Biol Chem; 2017 Sep; 292(38):15705-15716. PubMed ID: 28724631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.
    Baladi T; Aziz J; Dufour F; Abet V; Stoven V; Radvanyi F; Poyer F; Wu TD; Guerquin-Kern JL; Bernard-Pierrot I; Garrido SM; Piguel S
    Bioorg Med Chem; 2018 Nov; 26(20):5510-5530. PubMed ID: 30309671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
    Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

  • 12. Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.
    Szabadkai I; Torka R; Garamvölgyi R; Baska F; Gyulavári P; Boros S; Illyés E; Choidas A; Ullrich A; Őrfi L
    J Med Chem; 2018 Jul; 61(14):6277-6292. PubMed ID: 29928803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.
    Keating AK; Kim GK; Jones AE; Donson AM; Ware K; Mulcahy JM; Salzberg DB; Foreman NK; Liang X; Thorburn A; Graham DK
    Mol Cancer Ther; 2010 May; 9(5):1298-307. PubMed ID: 20423999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.
    Xu D; Sun D; Wang W; Peng X; Zhan Z; Ji Y; Shen Y; Geng M; Ai J; Duan W
    Eur J Med Chem; 2021 Aug; 220():113497. PubMed ID: 33957388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy.
    Goff D; Zhang J; Heckrodt T; Yu J; Ding P; Singh R; Holland S; Li W; Irving M
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3766-3771. PubMed ID: 28711351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
    McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
    Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.
    Linger RM; Keating AK; Earp HS; Graham DK
    Expert Opin Ther Targets; 2010 Oct; 14(10):1073-90. PubMed ID: 20809868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
    Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
    Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
    Kim NY; Lee HY; Lee C
    Int J Oncol; 2015 Jul; 47(1):353-60. PubMed ID: 25975389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of an Imidazo[1,2-
    McCoull W; Boyd S; Brown MR; Coen M; Collingwood O; Davies NL; Doherty A; Fairley G; Goldberg K; Hardaker E; He G; Hennessy EJ; Hopcroft P; Hodgson G; Jackson A; Jiang X; Karmokar A; Lainé AL; Lindsay N; Mao Y; Markandu R; McMurray L; McLean N; Mooney L; Musgrove H; Nissink JWM; Pflug A; Reddy VP; Rawlins PB; Rivers E; Schimpl M; Smith GF; Tentarelli S; Travers J; Troup RI; Walton J; Wang C; Wilkinson S; Williamson B; Winter-Holt J; Yang D; Zheng Y; Zhu Q; Smith PD
    J Med Chem; 2021 Sep; 64(18):13524-13539. PubMed ID: 34478292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.